Even though CAND is accepted as a weak partial gamma receptor agonist (in contrast with others AT1-R antagonists such as telmisartan and irbesartan) (Michel et al., 2013), the described modulation of glial reactivity by CAND could be related to the modulation of these receptors, as it was described in an animal model of traumatic brain injury (Villapol et al., 2012). Here, AGTR1 is linked to brain injury.